LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Search

United Therapeutics Corp

Închisă

SectorSănătate

432.65 1.8

Rezumat

Modificarea prețului

24h

Curent

Minim

427.94

Maxim

432.88

Indicatori cheie

By Trading Economics

Venit

-13M

310M

Vânzări

4.2M

799M

P/E

Medie Sector

16.175

35.69

EPS

6.63

Marjă de profit

38.755

Angajați

1,305

EBITDA

54M

437M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+14.47% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

5.3B

19B

Deschiderea anterioară

430.85

Închiderea anterioară

432.65

Sentimentul știrilor

By Acuity

50%

50%

132 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

United Therapeutics Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 oct. 2024, 15:14 UTC

Principalele dinamici ale pieței

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparație

Modificare preț

United Therapeutics Corp Așteptări

Obiectiv de preț

By TipRanks

14.47% sus

Prognoză pe 12 luni

Medie 495.27 USD  14.47%

Maxim 575 USD

Minim 328 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruUnited Therapeutics Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

13 ratings

9

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

292.345 / 309.245Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

132 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat